« Back
Home /
Capivasertib

Capivasertib

Item no.	HY-15431-50mg
Manufacturer	MedChem Express
CASRN	1143532-39-1
Amount	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 g 25 mg 500 mg 50 mg 5 mg
Category	Oncology Neuroscience Metabolism Diabetes Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.95
Formula	C21H25ClN6O2
Citations	[1]Davies BR, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87.
Smiles	O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AZD5363
Available
Product Description	Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1, Akt2 and Akt3, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	428.92
Clinical Information	Launched
Manufacturers Research Area	Cancer
Solubility	DMSO : 125 mg/mL (ultrasonic)
Target	Akt; Autophagy
Manufacturers Target	Akt; Autophagy
Isoform	Akt1; Akt2; Akt3
Manufacturers Pathway	Autophagy; PI3K/Akt/mTOR
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15431-50mg-safety-datasheet.pdf